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Abstract
Mycoplasma pneumoniae is an important respiratory pathogen, accounting for up to 25% of community-acquired pneumonia, and is a com-
mon cause of hospitalized pneumonia in otherwise healthy adults and children. Mycoplasma pneumoniae isolates can be classiﬁed into two
main genomic groups (type 1 and type 2) based on sequence variation within the gene encoding the major adhesion molecule P1. Although
numerous publications have described real-time PCR assays for the detection of M. pneumoniae, none has been able to discriminate the
two genomic types. Here, a real-time PCR assay that can distinguish each type of M. pneumoniae utilizing high-resolution melt-curve analy-
sis is reported. Using this method, 102 isolates obtained from patients from 1965 to the present, including those from recent outbreaks,
were typed along with reference strains M129 (type 1) and FH (type 2). The results show that 55 isolates (54%) can be classiﬁed as type 1
and 47 isolates (46%) as type 2, and 100% correlation was demonstrated when compared with a standard PCR-restriction fragment length
polymorphism typing procedure. Typing of isolates obtained from recent outbreaks in the USA has revealed the presence of both types.
This assay provides a rapid, reliable and convenient method for typing M. pneumoniae isolates and may be useful for surveillance purposes
and epidemiological investigations, and may provide insight into the biology of M. pneumoniae distribution within populations.
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Introduction
Mycoplasma pneumoniae is a signiﬁcant cause of respiratory
disease and community-acquired pneumonia, accounting for
as high as 33% of hospitalized cases [1,2]. This frequent
cause of community outbreaks usually presents as a mild,
self-limiting respiratory illness, although it has been rarely
associated with extrapulmonary complications, including
neurological, cardiac and autoimmune manifestations [1,3–5].
Due to its minimal and highly uniform genome, genetic diver-
sity among isolates of M. pneumoniae is sparse [6]. Most
isolates can be categorized into one of two genomic groups
(type 1 or type 2) based on sequence variation of the P1
(MPN141) gene [6–8]. The P1 protein is an important immu-
nogen and virulence factor, which forms heterogeneous
complexes with other proteins and localizes at the
attachment organelle to mediate adherence of M. pneumoniae
to respiratory epithelial cells [9].
Currently, the standard typing method for distinguishing
M. pneumoniae isolates involves PCR-restriction fragment
length polymorphism (PCR-RFLP), which can be laborious
and time-consuming [10–13]. Recently, Dumke et al. [14]
described a nested-PCR followed by sequencing that can be
used directly with clinical specimen extracts to distinguish
each type and all known variants of M. pneumoniae. This
assay, however, requires several rounds of PCR, gel puriﬁca-
tion, and sequencing analysis and thus is not ideal for
generating rapid results. Real-time PCR followed by high-
resolution melt (HRM) analysis has been used by several
groups to discriminate genotypes or detect single nucleotide
polymorphisms (SNPs) and, more recently, to provide
greater genetic characterization of microbes [15,16]. This
technique has also been applied to detect macrolide-resistant
isolates of M. pneumoniae and to classify strains of M. syno-
viae into ten proﬁles, replacing PCR-RFLP as the standard
typing mechanism [17,18].
In the present study, we targeted type-speciﬁc sequences
within the P1 gene to design a real-time PCR followed by
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HRM analysis to discriminate between the two types of
M. pneumoniae. An approximately 1900-bp fragment of the
P1 gene was ampliﬁed and characterized by HRM analysis to
reliably separate type 1 and type 2 isolates. Using this assay,
we screened 102 isolates of M. pneumoniae acquired by our
laboratory since 1965, which are comprised of clinical strains
from individual cases, surveillance studies, and outbreaks
within the USA and Europe, including isolates from four
recent outbreaks in the USA. We then compared the typing
results with PCR-RFLP analysis.
Materials and Methods
Strains and isolates
Mycoplasma pneumoniae strains M129 (ATCC 29342) and FH
(ATCC 15531) were used as the reference strains for type 1
and type 2, respectively. All M. pneumoniae isolates used in
this study were isolated and grown in SP4 media as previ-
ously described [19].
DNA isolation
DNA was extracted from liquid cultures using either the
QIAmp DNA mini kit (Qiagen, Germantown, MA, USA), or
the Gentra Puregene Blood kit (Minneapolis, MN, USA),
according to the manufacturer’s instructions.
Real-Time PCR HRM Assay
Primers Mpt-F (5¢-TTAGCAGCTCTTCCCGACAA-3¢) and
Mpt-R (5¢-ACATCGTCATTCATCTTTGCGGC-3¢) were
designed to amplify an approximately 1900-bp target region
variable between types 1 and 2 of M. pneumoniae, partially
spanning the RepMP2/3 (repetitive) region within the
P1 gene. Real-time PCR assays were performed on the
Corbett Rotor-Gene 6000 real-time rotary analyser
(Sydney, Australia) using the Universal SYBRGreenER qPCR
kit (Invitrogen, Carlsbad, CA, USA). Each tube contained
the following per reaction: 12.5 lL of 2· mix, a ﬁnal
concentration of 250 nM of each primer above, 5 lL of
template at 1 ng/lL, 1 lL 10 mM dNTP nucleotide mix
(Promega, Madison, WI, USA), and 0.25 lL platinum Taq
polymerase (5 U/lL) (Invitrogen) and Nuclease-Free Water
(Promega) to a total volume of 25 lL. All samples were
tested in triplicate. Ampliﬁcation conditions were as
follows: 95C for 2 min, followed by 35 cycles of: 95C
for 30 s, 55C for 15 s, and 68C for 90 s. The HRM was
performed between 84C and 90C. Data were collected
at 0.05C/s intervals. HRM data were normalized by
setting the pre-melt baseline regions between 85.25C and
85.5C, and the post-melt baseline regions between
88.25C and 88.5C.
RFLP
Previously published primer sets ADH1/ADH2 and ADH3/
ADH4 were used to amplify an approximately 2300-bp and
an approximately 2500-bp fragment, respectively, of the
P1 gene [10]. Brieﬂy, each reaction contained 12.5 lL 2·
Platinum Quantitative PCR SuperMix-UNG (Invitrogen), a
ﬁnal concentration of 1 lM each of primers ADH1 and
ADH2, or AHD3 and ADH4, 0.25 lL platinum Taq poly-
merase (5 U/lL), 1 lL 10 mM dNTP nucleotide mix,
100 ng of template, and nuclease-free water to a volume of
50 lL. Ampliﬁcation was performed on the Stratagene
Mx3005 instrument (La Jolla, CA, USA). Reaction conditions
were as follows: 95C for 2 min, followed by 40 cycles of:
94C for 30 s, 55C for 30 s, and 68C for 3 min [13].
The PCR products were separately subjected to HaeIII
(NEB, Inc., Ispwich, MA, USA) digestion as described
previously [10].
Sequencing and Analysis
The c.1900 bp amplicon in the real-time PCR-HRM assay
was sequenced following gel puriﬁcation of the ampliﬁed
products using the GENECLEAN TurboKit (MP Biochemi-
cals, Irvine, CA, USA). Sequencing reactions were performed
with the Big Dye Terminator v3.1 kit (Applied Biosystems
Inc., Foster City, CA, USA) with approximately 40 ng DNA
and a ﬁnal concentration of 3.3 lM of each primer in a
20 lL reaction. Sequencing reaction conditions were as
follows: 96C for 1 min, followed by 30 cycles of 96C for
10 s, 55C for 10 s, and 60C for 4 min. The sequence reac-
tion products were cleaned using CentriSep 8 spin columns
(Princeton Separations, Adelphia, NJ, USA), and analysed on
a 3130xl ABI Prism Genetic Analyzer (Applied Biosystems
Inc.).
Results
Real-time PCR and HRM subtyping
Fig. 1 shows the distinct typing results of the real-time PCR-
HRM assay on a representative number of strains and
isolates. In the normalized graph mode (Fig. 1a), the initial
ﬂuorescence signal at the pre-melt stage is set to 100%,
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whereas the ﬁnal ﬂuorescence level at the post-melt stage
is set to 0%, allowing for the type-speciﬁc melt proﬁles
generated by the amplicons of each type to be viewed. The
amplicon of type 2 isolates consistently shows a lower melt
proﬁle than that of type 1 isolates, which displays a signiﬁ-
cant shift of the proﬁle to the right. Fig. 1b displays the data
using a difference graph, in which type 2 isolates have been
selected as the standard from which to show deviations. This
alternate viewing of the same data illustrates the deviations
between the types. The 102 isolates all reliably sorted into
one of two distinct groups: type 1 (54%) or type 2 (46%).
These typed 102 isolates included those acquired by the
CDC during four outbreaks which occurred in the USA from
1999 to 2007. Isolates of both M. pneumoniae types were
obtained during this period and show a type 2 homogeneity
in two outbreaks: Indiana, 1999 (5/5) and New Hampshire,
2007 (2/2). A type 1 homogeneity was observed in the other
two outbreaks: Maine, 2007 (4/4) and Rhode Island, 2006–
2007, with the exception of a single type 2 isolate among 11
type 1 isolates (10/11).
Sequence analysis
Sequencing of the c.1900-bp PCR products for reference
strains M129 (type 1) and FH (type 2), along with a clinical
isolate of each type, 2p (type 1) and 1136 (type 2), was
performed in order to compare sequence differences
responsible for the type-speciﬁc melting proﬁles. Sequence
alignment of the variable regions between the types is
shown in Fig. 2. The sequence results comparing M129
strain and isolate 2p are identical, whereas two nucleotide
mismatches are observed between FH strain and isolate
1136. Signiﬁcant differences are seen between type 1 and
type 2 reference strains and isolates, including several gaps/
insertions.
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FIG. 1. Real-time PCR high-resolution melt
(HRM) assay. (a) The HRM proﬁle for type 1
and type 2 isolates in the normalized graph
mode; and (b) the difference graph illustrates
deviations between types 1 and 2. The type 2
isolates have been selected as the standard,
displaying the deviations of type 1 isolates
from the type 2 isolates.
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RFLP analysis
To conﬁrm and validate this PCR-HRM typing assay, we
performed RFLP analysis of the ADH1/ADH2- and ADH3/
ADH4-generated fragments of P1, digested by HaeIII on all
102 isolates. PCR-RFLP typing results correlated 100% with
the real-time PCR followed by HRM. Fig. 3a,b shows the
banding patterns of a representative number of isolates of
each type after enzyme digestion.
FIG. 2. Sequence alignment. Alignment of the variable regions derived from the c.1900-bp product of Mycoplasma pneumoniae clinical isolates 2p
(type 1) and 1136 (type 2) and the prototypical type 2 reference strain FH. The type 1 reference strain M129 sequence [24] is identical to 2p.
The top row illustrates the consensus sequence. The accession numbers for the sequences are FJ215694, FJ215693, and FJ215695 for strains
1136, FH, and 2p, respectively.
CMI Schwartz et al. M. pneumoniae genotyping in real-time 759
ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 756–762
No claim to original US government works
Discussion
We targeted a c.1900-bp variable region within the P1 gene
of M. pneumoniae to design a PCR-HRM assay capable of
genotyping type 1 and type 2 isolates of this agent. Although
PCR-HRM assays typically target smaller regions (<500 bp)
to discriminate minor changes [20], including SNPs, this
study reports an alternative use of this technology. Complex
melting proﬁles have been reported to provide a better
means of distinguishing differences than simple, single-peaked
melting proﬁles that are found within smaller amplicons [21].
The variable region of the P1 gene (MPN141) of M. pneumo-
niae spans a greater area and thus provides an ideal target
for designing a reliable discriminatory assay for typing this
respiratory pathogen.
In this study, the typing results of the 102 isolates
obtained since 1965 showed a virtually equivalent distribu-
tion (54% type 1, and 46% type 2). A remarkably clear
separation of type 1 and type 2 isolates can be seen in
both the ‘normalized’ and ‘difference’ graph modes (Fig. 1),
with some minor intratype variability. This separation is
based on the melting dynamics of type-speciﬁc sequence
domains within the targeted region as shown in Fig. 2.
These data display 100% concordance with the current ref-
erence standard typing method of PCR-RFLP, which we
performed using each isolate to validate our assay (Fig. 3).
Further analysis of the sequence data within Fig. 2 reveals
numerous base substitutions and gaps within the region that
account for the unique melting proﬁles of type 1 vs. type 2
isolates. Although very slight intratype melt variations cor-
responding to the two nucleotide mismatches between FH
strain and isolate 1136 were noted (data not shown), major
differences, as shown between type 1 and type 2, were not
observed.
Methods for differentiating isolates may serve numerous
purposes. For instance, monitoring epidemiological trends of
M. pneumoniae outbreaks may lead to greater understanding
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FIG. 3. Restriction fragment length polymorphism analysis of HaeIII-digested PCR fragments. M129 and FH were used as the reference strains
for type 1 and type 2, respectively. Characteristic banding patterns for each type are shown. A broad-range molecular weight marker is shown
in lane 13 for both a and b. (a) Representative gel illustrating HaeIII-digested type-speciﬁc banding patterns from fragment 1 (generated by prim-
ers ADH1/ADH2) for ten isolates along with reference strains. Type 1 isolates (lane 2 – M129; lanes 4, 6, 7, 8) and type 2 isolates (lane 1 – FH;
lanes 3, 5, 9, 10, 11, 12) are shown; and (b) representative gel illustrating HaeIII-digested type-speciﬁc banding patterns from fragment 2 (gener-
ated by primers ADH3/ADH4) for ten isolates along with reference strains. Type 1 isolates (lane 2 – M129; lanes 4, 5, 6, 7, 10, 11, 12) and type
2 isolates (lane 1 – FH; lanes 3, 8, 9) are shown.
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of the biology and communicable nature of this agent and
yield insight into its ability to cause cyclic epidemics. A
recent retrospective genotyping analysis of isolates collected
over a 10-year period by Kenri et al. [11] provides evidence
of the phenomenon of type-switching occurring approxi-
mately every 7 years in Japan. Sasaki et al. [10] had previ-
ously documented distinct shifts in M. pneumoniae types over
a 20-year period in Japan, with intervals of 4 years between
epidemics; however, they were unable to correlate this shift
deﬁnitively with epidemic cycles. Type-switching has been
proposed to occur due to population-based immune pres-
sure and may explain the cyclic nature of both type-speciﬁc
outbreaks and subsequent immunity [22]. Our data from
four recent outbreaks clustered in the USA indicate that
both types are currently circulating within the population
and, in the case of the Rhode Island 2006–2007 outbreak,
are concurrently present within a single outbreak. Collec-
tively, M. pneumoniae typing studies have illustrated the difﬁ-
culty in clearly delineating the correlation of type switching
with immunity, epidemics and prevalence in the population.
Large-scale surveillance and characterization of the M. pneu-
moniae types may improve this understanding.
Additionally, retrospective and prospective typing analysis
of M. pneumoniae isolates may also allow researchers to
study possible relationships among genotypes and their
potential role in virulence, infectivity rates, host preferences
(age, sex, race, etc.) and immune pressures that may lead to
type-switching. Thus far, no clear trends in subtype-speciﬁc
virulence or infectivity have been demonstrated [23]. The
procedure could facilitate a more rapid and high-throughput
ability to type isolates, expediting more thorough and com-
prehensive studies. Lastly, because the P1 antigen is known
to be immunodominant and is a major basis for characteriz-
ing M. pneumoniae types, relevant typing information may aid
in future vaccine development.
This is the ﬁrst report of a rapid and simple real-time
PCR method that is able to discriminate reliably between the
two dominant types of M. pneumoniae. This approach
provides a marked improvement over the more laborious
procedures of PCR-RFLP, pulsed-ﬁeld gel electrophoresis,
and nested PCR followed by sequencing and less reliable
randomly ampliﬁed polymorphic DNA tests that are cur-
rently used. Furthermore, this methodology may also allow
for greater characterization of isolates, including the identiﬁ-
cation of variants of each type. Research studies are ongoing,
with the aim of expanding the applications of this assay to
include: (i) testing of clinical specimens; (ii) implementing for
surveillance purposes; (iii) prospective use during outbreaks;
and (iv) possible use to monitor the genetic evolution of this
important virulence gene.
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